DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Veliparib
Veliparib
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity Both in Cancer Cells and Healthy Bone Marrow
Research in Your Backyard Developing Cures, Creating Jobs
Horizon Scanning Status Report June 2019
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Draft COMP Agenda 16-18 January 2018
A Phase I Clinical Trial of the Poly(ADP-Ribose) Polymerase Inhibitor Veliparib And
Profile of Veliparib and Its Potential in the Treatment of Solid Tumors Lars M
Access to Cancer Medicines in Australia
Clinical Study Protocol M13-694 a Phase 3 Placebo-Controlled Study
Phase 1 Study of Veliparib (ABT-888), a Poly (ADP-Ribose) Polymerase
Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
S1513 Revision #2 (Contd.) Page 2
ANNUAL REPORT 2018–2019 Fall 2019
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer
AHRQ Healthcare Horizon Scanning System – Status Update Horizon
(COMP) Draft Agenda for the Meeting on 14-15 March 2017
Summary of Clinical Trial Results for Laypersons
Identification of Novel Biomarkers of Homologous Recombination Defect
Top View
Protocol Update #09 ALLIANCE for CLINICAL TRIALS in ONCOLOGY
PARP Inhibitors As Therapeutics: Beyond Modulation of Parylation
Results of Juvenile Animal Studies (JAS) and Impact on Anti-Cancer Medicine Development and Use in Children Project Report
PARP Inhibitors for BRCA1/2-Mutated and Sporadic Ovarian Cancer: Current Practice and Future Directions
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
(12) Patent Application Publication (10) Pub. No.: US 2016/0220537 A1 GARNER Et Al
(PARP) Inhibitors in Ovarian Cancer: Quo Vadis?
Veliparib in Combination with Carboplatin and Paclitaxel for Breast Cancer – First to Third Line NIHRIO (HSRIC) ID: 11354 NICE ID: 8328
Drug Eruptions Associated with Tumor Therapy: Great Imitators
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin And
The PARP Inhibitors, Veliparib and Olaparib, Are Effective Chemopreventive Agents for Delaying Mammary Tumor Development in BRCA1-Deficient Mice
(SLFN11): a Step Forward Towards Personalized Medicine in Small-Cell Lung Cancer?
Pdf/2009-10/Firmagon - Ct-6725.Pdf 58
Multidisciplinary Management of Brain Metastases Arising from Breast Cancer
Intracranial Evaluation of the in Vivo Pharmacokinetics, Brain
Dctd Programs and Initiatives (2013-2017) Biometric Research Program 46
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant
MC1488 Protocol
Novel Non-AR Therapeutic Targets in Castrate Resistant Prostate Cancer
211651Orig1s000
1078-0432.CCR-12-0163.Full.Pdf
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy
Oncology Drugs in the Pipeline
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
Ut Scc 110A Ut Scc 21 Ut Scc 49 Ut Scc 74A
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Utilizing Novel Fluorothymidine PET Imaging in a Phase I Study of Veliparib on an Intermittent and Continuous Schedule Given In
Veliparib with Carboplatin and Paclitaxel for Early-Stage Triple Negative Breast Cancer ─ Neoadjuvant Therapy
Smart Approaches for the Effective Treatment of Breast Cancer
ABT-888) · NSCLC · PARP · on Days 1–7
Analysis of PARP Inhibitor Toxicity by Multidimensional fluorescence Microscopy Reveals Mechanisms of Sensitivity and Resistance
The Breast Cancer Drug Market
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor
Photodynamic Diagnosis and Therapy for Peritoneal Carcinomatosis: Emerging Perspectives
Current State and Future Perspectives in Breast Cancer
Assessment Report Talzenna
Supporting Information